Keros Therapeutics (NASDAQ:KROS) Upgraded to Strong-Buy at Wedbush

Wedbush upgraded shares of Keros Therapeutics (NASDAQ:KROS) to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. Wedbush also issued estimates for Keros Therapeutics’ Q4 2025 earnings at ($1.27) EPS.

Several other analysts have also issued reports on KROS. Bank of America reduced their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Scotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating on the stock. Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday. They issued a “buy” rating for the company. Finally, Guggenheim initiated coverage on Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Eleven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $89.11.

Keros Therapeutics Stock Up 4.4 %

Shares of NASDAQ:KROS opened at $62.58 on Monday. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of -12.20 and a beta of 1.23. The stock’s 50 day moving average is $56.87 and its 200-day moving average is $51.89. Keros Therapeutics has a twelve month low of $27.31 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same period in the prior year, the business earned ($1.27) EPS. Equities research analysts anticipate that Keros Therapeutics will post -4.9 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the transaction, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.90% of the stock is owned by insiders.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KROS. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after buying an additional 251 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after purchasing an additional 1,130 shares in the last quarter. American International Group Inc. increased its position in shares of Keros Therapeutics by 13.1% during the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock valued at $838,000 after purchasing an additional 1,465 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Keros Therapeutics by 26.5% during the 1st quarter. ProShare Advisors LLC now owns 7,136 shares of the company’s stock valued at $472,000 after buying an additional 1,496 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.